कंपनी का अवलोकन
aTyr Pharma, Inc. operates as a clinical stage biotechnology firm dedicated to discovering and developing product candidates that translate tRNA synthetase biology into novel therapies for fibrosis and inflammation within the United States. The company functions within the broader Healthcare sector and the specific Biotechnology industry, positioning itself to address significant unmet medical needs through proprietary molecular mechanisms. Currently, the enterprise employs 58 individuals and maintains a market capitalization of $73.54M, while reporting annual revenue of $190,000 based on trailing twelve-month data. These financial dimensions indicate that the organization is a micro-cap entity with minimal revenue generation relative to its market valuation, suggesting it remains in an early-stage development phase where capital allocation is focused on research and development rather than commercial scale. The disparity between the market cap and the negligible revenue figure underscores the speculative nature of the investment, as the market price reflects potential future value from lead candidates like efzofitimod rather than current operational earnings.
वित्तीय स्वास्थ्य
The company reported a revenue of $190,000 for the trailing twelve months, yet it posted a net income of $-74,118,000, revealing a cost structure characterized by substantial operating losses that vastly exceed current income generation. The EBITDA stands at $-76,963,000, further highlighting the heavy financial burn associated with clinical-stage operations and the lack of profitability in the current reporting period. Free cash flow is negative at $-33,797,876, which indicates that the company is consuming cash reserves to fund its developmental activities and has no current cash generation from operations to support expansion or debt servicing. The gross margin is recorded at 0.0%, while the operating margin is -40856.3% and the profit margin is also 0.0%, all figures reflecting the extreme dilution of revenue by high fixed costs and the absence of net income in the denominator for margin calculations. Despite these deficits, the firm holds cash of $78.69M against total debt of $12.03M, resulting in a debt-to-equity ratio of 17.88 that suggests a leveraged balance sheet relative to equity, though the absolute cash position provides a significant buffer against obligations. The current ratio of 5.30 indicates a robust short-term liquidity position, as current assets significantly exceed current liabilities, ensuring the ability to meet immediate financial commitments. Return on Equity is -108.1% and Return on Assets is -51.1%, metrics that reveal management has yet to generate positive returns on the capital invested in the business, a common characteristic for clinical-stage biotech firms prior to commercial product launch.
मूल्यांकन आकलन
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -1.87, a valuation metric that implies the market is pricing in future earnings recovery but currently values the stock based on non-earnings fundamentals. The price-to-book ratio stands at 1.09, indicating that the market values the company at slightly above its book value, which is typical for biotechnology firms where intellectual property and pipeline potential are valued over tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 387.04 and an EV/EBITDA of -0.09 suggest that the stock price is detached from current revenue and earnings, reflecting high expectations for future commercialization success rather than current financial performance. The stock has traded between a 52-week high of $7.29 and a 52-week low of $0.64, placing the current trading range in a wide band of volatility typical for speculative biotechnology assets. The beta of 0.65 indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market fluctuations but remains subject to its own sector-specific risks and clinical trial outcomes.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both N/A, indicating that historical growth rates cannot be calculated due to the company's recent establishment or lack of sufficient historical financial data to establish a trend. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all earnings and cash flows to reinvest into product development and clinical trials rather than distributing income to shareholders. The absence of a dividend policy aligns with the growth profile of a clinical stage biotechnology company, where capital is prioritized for research and development to advance the efzofitimod candidate through the regulatory pipeline. Consequently, the overall growth and income profile for aTyr Pharma, Inc. is defined by capital preservation and pipeline advancement rather than current revenue expansion or income distribution to investors.